The rLVS ΔcapB/iglABC vaccine provides potent protection in Fischer rats against inhalational tularemia caused by various virulent Francisella tularensis strains

References

• Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961;107(5):702–14. doi:10.1001/archinte.1961.03620050068007.
   PubMedGoogle Scholar
• Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763–73. [ pii]. doi:10.1001/jama.285.21.2763.
   PubMed Web of Science ®Google Scholar
• Jellison WL. Tularemia in Montana. Mont Wildl. 1971:5–24. PMID: 11614973.
   PubMedGoogle Scholar
• Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci. 2007;1105(1):1–29. doi:10.1196/annals.1409.009.
   PubMedGoogle Scholar
• Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev. 2002;15(4):631–46. doi:10.1128/CMR.15.4.631-646.2002.
   PubMed Web of Science ®Google Scholar
• Jellison WL. Tularemia; geographical distribution of deer fly fever and the biting fly, Chrysops discalis Williston. Public Health Rep. 1950;65(41):1321–9. doi:10.2307/4587498.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, et al. Tick-borne tularemia. An outbreak of lymphadenopathy in children. JAMA. 1985;254(20):2922–5. doi:10.1001/jama.1985.03360200074030.
   PubMed Web of Science ®Google Scholar
• Goethert HK, Shani I, Telford SR III. Genotypic diversity of Francisella tularensis infecting Dermacentor variabilis ticks on martha’s vineyard, Massachusetts. J Clin Microbiol. 2004;42(11):4968–73. doi:10.1128/JCM.42.11.4968-4973.2004.
   PubMed Web of Science ®Google Scholar
• Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg Infect Dis. 1997;3(2):83–94. doi:10.3201/eid0302.970201.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Health aspects of chemical and biological weapons. Geneva, Switzerland: World Health Organization; 1970. p. 105–7.
   Google Scholar
• Franz DR, Jahrling PB, McClain DJ, Hoover DL, Russell Byrne W, Pavlin JA, Christopher GW, Cieslak TJ, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278(5):399–411. doi:10.1001/jama.1997.03550050061035.
   PubMed Web of Science ®Google Scholar
• Eigelsbach HT, Downs CM. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol. 1961;87(4):415–25. doi:10.4049/jimmunol.87.4.415.
   PubMed Web of Science ®Google Scholar
• Tigertt WD. Soviet viable Pasteurella tularensis vaccines a review of selected articles. Bacteriol Rev. 1962;26(3):354–73. doi:10.1128/br.26.3.354-373.1962.
   PubMedGoogle Scholar
• McCrumb FR. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev. 1961;25(3):262–7. doi:10.1128/br.25.3.262-267.1961.
   PubMedGoogle Scholar
• Eigelsbach HT, Tulis JJ, Overholt EL, Griffith WR. Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proc Soc Exp Biol Med. 1961;108(3):732–4. doi:10.3181/00379727-108-27049.
   PubMed Web of Science ®Google Scholar
• Conlan JW. Vaccines against Francisella tularensis–past, present and future. Expert Rev Vaccines. 2004;3(3):307–14. [ pii]. doi:10.1586/14760584.3.3.307.
   PubMedGoogle Scholar
• Eigelsbach HT, Braun W, Herring RD. Studies on the variation of Bacterium tularense. J Bacteriol. 1951;61(5):557–69. doi:10.1128/jb.61.5.557-569.1951.
   PubMed Web of Science ®Google Scholar
• Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med. 1961;107(5):689–701. doi:10.1001/archinte.1961.03620050055006.
   PubMedGoogle Scholar
• Bachert BA, Richardson JB, Mlynek KD, Klimko CP, Toothman RG, Fetterer DP, Luquette AE, Chase K, Storrs JL, Rogers AK, et al. Development, phenotypic characterization and genomic analysis of a Francisella tularensis panel for tularemia vaccine testing. Front Microbiol. 2021;12. doi:10.3389/fmicb.2021.725776.
   PubMed Web of Science ®Google Scholar
• Twine SM, Shen H, Kelly JF, Chen W, Sjöstedt A, Conlan JW. Virulence comparison in mice of distinct isolates of type A Francisella tularensis. Microb Pathog. 2006;40(3):133–8. [ pii]. doi:10.1016/j.micpath.2005.12.004.
   PubMed Web of Science ®Google Scholar
• Farlow J, Wagner DM, Dukerich M, Stanley M, Chu M, Kubota K, Petersen J, Keim P. Francisella tularensis in the United States. Emerg Infect Dis. 2005;11(12):1835–41. doi:10.3201/eid1112.050728.
   PubMed Web of Science ®Google Scholar
• Kugeler KJ, Mead P, Janusz A, Staples J, Kubota K, Chalcraft L, Petersen J. Molecular epidemiology of Francisella tularensis in the United States. Clin Infect Dis. 2009;48(7):863–70. doi:10.1086/597261.
   PubMed Web of Science ®Google Scholar
• Birdsell DN, Johansson A, Öhrman C, Kaufman E, Molins C, Pearson T, Gyuranecz M, Naumann A, Vogler AJ, Myrtennäs K, et al. Francisella tularensis subsp. tularensis group A.I, United States. Emerg Infect Dis. 2014;20(5):861–5. doi:10.3201/eid2005.131559.
   PubMed Web of Science ®Google Scholar
• Jia Q, Bowen R, Dillon BJ, Masleša-Galić S, Chang BT, Kaidi AC, Horwitz MA. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep. 2018;8(1):7009. doi:10.1038/s41598-018-24581-y.
   PubMedGoogle Scholar
• Jia Q, Bielefeldt-Ohmann H, Maison RM, Hartwig A, Masleša-Galić S, Bowen RA, Horwitz MA. Oral Administration of universal bacterium-vectored nucleocapsid-expressing COVID-19 vaccine is efficacious in hamsters. Microbiol Spectr. 2023;e0503522(2). doi:10.1128/spectrum.05035-22.
   Google Scholar
• Jia Q, Bielefeldt-Ohmann H, Maison RM, Masleša-Galić S, Cooper SK, Bowen RA, Horwitz MA. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. NPJ Vaccines. 2021;6(1):47. doi:10.1038/s41541-021-00321-8.
   PubMed Web of Science ®Google Scholar
• Jia Q, Bowen R, Lee B-Y, Dillon BJ, Masleša-Galić S, Horwitz MA. Francisella tularensis live vaccine strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge. Vaccine. 2016;34(41):4969–78. doi:10.1016/j.vaccine.2016.08.041.
   PubMed Web of Science ®Google Scholar
• Roy CJ, Hale M, Hartings JM, Pitt L, Duniho S. Impact of inhalation exposure modality and particle size on the respiratory deposition of ricin in BALB/c mice. Inhal Toxicol. 2003;15(6):619–38. doi:10.1080/08958370390205092.
   PubMed Web of Science ®Google Scholar
• Dabisch P, Bower K, Dorsey B, Wronka L. Recovery efficiencies for Burkholderia thailandensis from various aerosol sampling media. Front Cell Inf Microbio. 2012;2:78. doi:10.3389/fcimb.2012.00078.
   PubMed Web of Science ®Google Scholar
• Dabisch P, Yeager J, Kline J, Klinedinst K, Welsch A, Pitt ML. Comparison of the efficiency of sampling devices for aerosolized Burkholderia pseudomallei. Inhal Toxicol. 2012;24(5):247–54. doi:10.3109/08958378.2012.666682.
   PubMed Web of Science ®Google Scholar
• Glynn A, Roy CJ, Powell BS, Adamovicz JJ, Freytag LC, Clements JD. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun. 2005;73(8):5256–61. doi:10.1128/IAI.73.8.5256-5261.2005.
   PubMed Web of Science ®Google Scholar
• Hutt JA, Lovchik JA, Dekonenko A, Hahn AC, Wu TH. The Natural History of Pneumonic Tularemia in Female Fischer 344 Rats after Inhalational Exposure to Aerosolized Francisella tularensis Subspecies tularensis Strain SCHU S4. Am J Pathol. 2017;187(2):252–67. doi:10.1016/j.ajpath.2016.09.021.
   PubMed Web of Science ®Google Scholar
• Ray HJ, Chu P, Wu TH, Lyons CR, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The Fischer 344 rat reflects human susceptibility to Francisella pulmonary challenge and provides a new platform for virulence and protection studies. PLoS One. 2010;5(4):e9952. doi:10.1371/journal.pone.0009952.
   PubMed Web of Science ®Google Scholar
• Binder J, Graser E, Hancock WW, Wasowska B, Sayegh MH, Volk H-D, Kupiec-Weglinski JW. Downregulation of intragraft IFN-γ expression correlates with increased IgG1 alloantibody response following intrathymic immunomodulation of sensitized rat recipients1,2. Transplantation. 1995;60(12):1516–24. doi:10.1097/00007890-199560120-00025.
   PubMed Web of Science ®Google Scholar
• Gracie JA, Bradley JA. Interleukin-12 induces interferon-γ-dependent switching of IgG alloantibody subclass. Eur J Immunol. 1996;26(6):1217–21. doi:10.1002/eji.1830260605.
   PubMed Web of Science ®Google Scholar
• Drabner B, Guzman CA. Elicitation of predictable immune responses by using live bacterial vectors. Biomol Eng. 2001;17(3):75–82. doi:10.1016/S1389-0344(00)00072-1.
   PubMedGoogle Scholar
• Salomonsson E, Kuoppa K, Forslund A-L, Zingmark C, Golovliov I, Sjostedt AJ, Noppa L, Forsberg A. Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis. Infect Immun. 2009;77(8):3424–31. doi:10.1128/IAI.00196-09.
   PubMed Web of Science ®Google Scholar
• Rohmer L, Fong C, Abmayr S, Wasnick M, Larson Freeman T, Radey M, Guina T, Svensson K, Hayden HS, Jacobs M, et al. Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strains. Genome Biol. 2007;8(6):R102. doi:10.1186/gb-2007-8-6-r102.
   PubMed Web of Science ®Google Scholar
• Jia Q, Lee B-Y, Bowen R, Dillon BJ, Som SM, Horwitz MA. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect Immun. 2010;78(10):4341–55. doi:10.1128/IAI.00192-10.
   PubMed Web of Science ®Google Scholar
• Svensson K, Larsson P, Johansson D, Bystrom M, Forsman M, Johansson A. Evolution of subspecies of Francisella tularensis. J Bacteriol. 2005;187(11):3903–8. doi:10.1128/JB.187.11.3903-3908.2005.
   PubMed Web of Science ®Google Scholar
• Raymond CR, Conlan JW. Differential susceptibility of Sprague–Dawley and Fischer 344 rats to infection by Francisella tularensis. Microb Pathog. 2009;46(4):231–4. [ pii]. doi:10.1016/j.micpath.2009.01.002.
   PubMed Web of Science ®Google Scholar
• Jemski JV. Respiratory tularemia: comparison of selected routes of vaccination in Fischer 344 rats. Infect Immun. 1981;34(3):766–72. doi:10.1128/iai.34.3.766-772.1981.
   PubMed Web of Science ®Google Scholar
• De Pascalis R, Hahn A, Brook HM, Ryden P, Donart N, Mittereder L, Frey B, Wu TH, Elkins KL, et al. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis. PLoS One. 2018;13(5):e0198140. doi:10.1371/journal.pone.0198140.
   PubMed Web of Science ®Google Scholar
• Wu TH, Zsemlye JL, Statom GL, Hutt JA, Schrader RM, Scrymgeour AA, Lyons CR. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type a strains. Vaccine. 2009;27(34):4684–93. doi:10.1016/j.vaccine.2009.05.060.
   PubMed Web of Science ®Google Scholar
• Mara-Koosham G, Hutt JA, Lyons CR, Wu TH, Morrison RP. Antibodies contribute to effective vaccination against respiratory infection by type a Francisella tularensis strains. Infect Immun. 2011;79(4):1770–8. doi:10.1128/IAI.00605-10.
   PubMed Web of Science ®Google Scholar
• Kirimanjeswara GS, Olmos S, Bakshi CS, Metzger DW. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol Rev. 2008;225(1):244–55. doi:10.1111/j.1600-065X.2008.00689.x.
   PubMedGoogle Scholar
• Pasetti MF, Cuberos L, Horn TL, Shearer JD, Matthews SJ, House RV, Sztein MB. An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine. 2008;26(14):1773–85. doi:10.1016/j.vaccine.2008.01.005.
   PubMed Web of Science ®Google Scholar
• Mlynek KD, Lopez CT, Fetterer DP, Williams JA, Bozue JA. Phase variation of LPS and capsule is responsible for stochastic biofilm formation in Francisella tularensis. Front Cell Infect Microbiol. 2022;11:11. doi:10.3389/fcimb.2021.808550.
   Web of Science ®Google Scholar
• Waag DM, Sandstrom G, England MJ, Williams JC. Immunogenicity of a new lot of Francisella tularensis live vaccine strain in human volunteers. FEMS Immunol Med Microbiol. 1996;13(3):205–9. doi:10.1111/j.1574-695X.1996.tb00238.x.
   PubMedGoogle Scholar
• Oyston PC. Francisella tularensis vaccines. Vaccine. 2009;27(Suppl 4):D48–51. doi:10.1016/j.vaccine.2009.07.090.
   PubMedGoogle Scholar
• Soni S, Ernst RK, Muszyński A, Mohapatra NP, Perry MB, Vinogradov E, Carlson RW, Gunn JS. Francisella tularensis blue–gray phase variation involves structural modifications of lipopolysaccharide O-Antigen, core and lipid a and affects intramacrophage survival and vaccine efficacy. Front Microbio. 2010;1:129. doi:10.3389/fmicb.2010.00129.
   PubMed Web of Science ®Google Scholar
• Pechous RD, McCarthy TR, Mohapatra NP, Soni S, Penoske RM, Salzman NH, Frank DW, Gunn JS, Zahrt TC, et al. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS One. 2008;3(6):e2487. doi:10.1371/journal.pone.0002487.
   PubMed Web of Science ®Google Scholar
• Qin A, Scott DW, Thompson JA, Mann BJ. Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect Immun. 2009;77(1):152–61. [ pii]. doi:10.1128/IAI.01113-08.
   PubMed Web of Science ®Google Scholar
• Golovliov I, Twine SM, Shen H, Sjostedt A, Conlan W, Kaufmann GF. A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia. PLoS One. 2013;8(11):e78671. doi:10.1371/journal.pone.0078671.
   PubMed Web of Science ®Google Scholar
• Straskova A, Cerveny L, Spidlova P, Dankova V, Belcic D, Santic M, Stulik J. Deletion of IglH in virulent Francisella tularensis subsp. holarctica FSC200 strain results in attenuation and provides protection against the challenge with the parental strain. Microbes Infection/Institut Pasteur. 2012;14(2):177–87. doi:10.1016/j.micinf.2011.08.017.
   PubMed Web of Science ®Google Scholar
• Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KRO, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine. 2008;26(41):5276–88. doi:10.1016/j.vaccine.2008.07.051.
   PubMed Web of Science ®Google Scholar
• Rockx-Brouwer D, Chong A, Wehrly TD, Child R, Crane DD, Celli J, Bosio CM. Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS One. 2012;7(5):e37752. doi:10.1371/journal.pone.0037752.
   PubMed Web of Science ®Google Scholar
• Whelan AO, Flick-Smith HC, Homan J, Shen ZT, Carpenter Z, Khoshkenar P, Abraham A, Walker NJ, Levitz SM, Ostroff GR, et al. Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles. PLoS One. 2018;13(10):e0200213. doi:10.1371/journal.pone.0200213.
   PubMed Web of Science ®Google Scholar
• Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine. 2009;27(8):1216–29. doi:10.1016/j.vaccine.2008.12.014.
   PubMed Web of Science ®Google Scholar
• O’Malley KJ, Bowling JL, Stinson E, Cole KS, Mann BJ, Namjoshi P, Hazlett KRO, Barry EM, Reed DS, et al. Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type a Francisella tularensis. PLoS One. 2018;13(10):e0205928. doi:10.1371/journal.pone.0205928.
   PubMed Web of Science ®Google Scholar
• Chu P, Cunningham AL, Yu J-J, Nguyen JQ, Barker JR, Lyons CR, Wilder J, Valderas M, Sherwood RL, Arulanandam BP, et al. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. PLoS Pathog. 2014;10(10):e1004439. doi:10.1371/journal.ppat.1004439.
   PubMed Web of Science ®Google Scholar
• De Pascalis R, Frey B, Rice HM, Bhargava V, Wu TH, Peterson RL, Conlan JW, Sjöstedt A, Elkins KL. Working correlates of protection predict SchuS4-derived-vaccine candidates with improved efficacy against an intracellular bacterium, Francisella tularensis. NPJ Vaccines. 2022;7(1):95. doi:10.1038/s41541-022-00506-9.
   PubMed Web of Science ®Google Scholar
• Frick OM, Livingston VA, Whitehouse CA, Norris SL, Alves DA, Facemire PR, Reed DS, Nalca A. The natural history of aerosolized Francisella tularensis infection in cynomolgus macaques. Pathogens. 2021;10(5):597. doi:10.3390/pathogens10050597.
   PubMed Web of Science ®Google Scholar
• Glynn AR, Alves DA, Frick O, Erwin-Cohen R, Porter A, Norris S, Waag D, Nalca A. Comparison of experimental respiratory tularemia in three nonhuman primate species. Comp Immunol Microbiol Infect Dis. 2015;39:13–24. doi:10.1016/j.cimid.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Nelson M, Lever MS, Savage VL, Salguero FJ, Pearce PC, Stevens DJ, Simpson AJH. Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus). Int J Experimental Path. 2009;90(2):109–18. doi:10.1111/j.1365-2613.2008.00631.x.
   PubMed Web of Science ®Google Scholar